CRASH II was a massive trial held in over 49 countries enrolling over 20,000 patients. They looked at blunt and penetrating trauma in adults of all ages and compared to TXA to placebo for patients in all shock categories (GCS, SBP, RR). The dose given was 1g over 10 minutes followed by 1 g over 8 hours.
The results showed that TXA improved survival at 28 days from injury with an absolute risk reduction (death) of 1.5%. This may not seem like much but consider that there was no increased rate of death or serious side effects associated with the drug. This includes no increased risk of thromboembolic events (stroke, MI, PE, DVT).
There was no change in the rate or amount of blood transfusions required either, highlighting the importance of the drug as an adjunct and the continued need to get blood on board quickly.
This paper was donated to the public as an open document in an attempt to widen it's use and can be obtained at: http://www.journalslibrary.nihr.ac.uk/hta/volume-17/issue-10#abstract